Symmetric dimethylarginine (SDMA) is a methylated derivative of the amino acid L-arginine and serves as a sensitive and reliable biomarker for assessing renal function. Unlike serum creatinine, which often fails to reflect mild to moderate renal impairment, SDMA is excreted almost exclusively by the kidneys. As a result, plasma SDMA concentrations correlate closely with glomerular filtration rate (GFR) and other renal clearance measurements, even in early stages of kidney dysfunction. Clinical studies have demonstrated a strong relationship between SDMA levels and inulin clearance, establishing it as a superior marker for early detection of renal insufficiency.
In research and clinical practice, SDMA offers significant value not only for diagnosing renal impairment but also for assessing cardiovascular risk. Elevated SDMA levels have been independently associated with increased cardiovascular morbidity and mortality, even when renal impairment is only mild. This highlights SDMA’s potential as a dual-purpose biomarker that bridges nephrology and cardiology, aiding in risk stratification and long-term monitoring of patients with chronic conditions.
The SDMA human ELISA kit enables quantitative measurement of SDMA levels in plasma using a competitive enzyme immunoassay format. During the assay, acylated SDMA in the sample competes with SDMA bound to a solid phase for antibody binding. Detection is achieved through a colorimetric reaction involving TMB and peroxidase, with absorbance read at 450 nm. The signal intensity is inversely proportional to the SDMA concentration, allowing precise and reproducible assessment of renal excretory performance in both clinical diagnostics and translational research.
This product is manufactured in Germany by DLD Diagnostika.